Human antibody mouse
AcadeMab’s antibody mouse is to replace the original mouse antibody genes by human antibody genes. This mouse strain can generate intact human antibodies that have been optimized naturally through in vivo affinity maturation. It can generate a wide variety of therapeutic antibodies from the transgenic mouse via hybridoma cell or single B cell selection. Therefore, it is a powerful tool to provide highly productive, developmental, and customized therapeutic antibodies to the global biopharmaceutical industry.
- The human antibodies can be generated via conventional hybridoma technology, which is user-friendly.
- Via the immunization and boosting of the exotic antigen immunization, the antibody affinity maturation can naturally occur, leading to high affinity clones.
For developing therapeutic antibodies against specific antigen or pathogen via either hybridoma technology or single B cell selection.
- This platform is under development. The first generation of transgenic mice is expected in 2023-Q1, and second generation in 2024-Q1.
- With this platform, AcadeMab can provide service to screen human antibodies for clients. Flexible licensing terms is also open for discussion.